Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?

被引：15

作者：

Mayerhoefer, Marius E. ^{[1
]}

Giraudo, Chiara ^{[1
]}

Senn, Daniela ^{[1
]}

Hartenbach, Markus ^{[1
]}

Weber, Michael ^{[1
]}

Rausch, Ivo ^{[2
]}

Kiesewetter, Barbara ^{[3
]}

Herold, Christian J. ^{[1
]}

Hacker, Marcus ^{[1
]}

Pones, Matthias ^{[1
]}

Simonitsch-Klupp, Ingrid ^{[4
]}

Muellauer, Leonhard ^{[4
]}

Dolak, Werner ^{[5
]}

Lukas, Julius ^{[6
]}

Raderer, Markus ^{[3
]}

机构：

[1] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria

[2] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria

[3] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria

[4] Med Univ Vienna, Inst Pathol, Vienna, Austria

[5] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria

[6] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria

来源：

CLINICAL NUCLEAR MEDICINE | 2016年 / 41卷 / 02期

基金：

奥地利科学基金会;

关键词：

lymphoma; 2-F-18-fluoro-2-deoxy-D-glucose; positron emission tomography; magnetic resonance imaging; computed tomography; DIFFUSION-WEIGHTED MRI; NON-HODGKIN-LYMPHOMA; FDG PET/CT; LESIONS; REPRODUCIBILITY;

D O I：

10.1097/RLU.0000000000001005

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Purpose: To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed-time-point 2-F-18-fluoro-2-deoxy-D-glucose-positron emission tomography (F-18-FDG-PET) performs better than standard-time-point F-18-FDG-PET. Materials and Methods: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic F-18-FDG-PET/computed tomography (CT) and consecutive F-18-FDG-PET/magnetic resonance imaging (MRI), using a single F-18-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective F-18-FDG-PET scans at time points 1 (45-60 minutes after tracer injection, TP1) and 2 (100-150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUVmax (maximum standardized uptake values) ratios were also assessed. Results: F-18-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and F-18-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%-84.67%) and 100% (CI, 100%-100%) for F-18-FDG-PET at TP1; and 87.0% (CI, 73.26%-100%) and 100% (CI, 100%-100%) for F-18-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and F-18-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%-80.9%) for F-18-FDG-PET at TP1, and 76.9% (CI, 54.0%-99.8%) for 18F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 +/- 0.40 and 1.52 +/- 0.62) than at TP2 (ratios, 1.67 +/- 0.74 and 2.56 +/- 1.10; P = 0.003 and P = 0.001). Conclusions: Delayed-time-point imaging may improve F-18-FDG-PET in MALT lymphoma.

引用

页码：101 / 105

页数：5

共 16 条

[11] Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients [J].

Mayerhoefer, Marius E. ;

Karanikas, Georgios ;

Kletter, Kurt ;

Prosch, Helmut ;

Kiesewetter, Barbara ;

Skrabs, Cathrin ;

Porpaczy, Edit ;

Weber, Michael ;

Pinker-Domenig, Katja ;

Berzaczy, Dominik ;

Hoffmann, Martha ;

Sillaber, Christian ;

Jaeger, Ulrich ;

Muellauer, Leonhard ;

Simonitsch-Klupp, Ingrid ;

Dolak, Werner ;

Gaiger, Alexander ;

Ubl, Philipp ;

Lukas, Julius ;

Raderer, Markus .

CLINICAL CANCER RESEARCH, 2014, 20 (11) :2984-2993

[12] Diffusion-weighted magnetic resonance imaging of breast lesions: the influence of different fat-suppression techniques on quantitative measurements and their reproducibility [J].

Muertz, P. ;

Tsesarskiy, M. ;

Kowal, A. ;

Traeber, F. ;

Gieseke, J. ;

Willinek, W. A. ;

Leutner, C. C. ;

Schmiedel, A. ;

Schild, H. H. .

EUROPEAN RADIOLOGY, 2014, 24 (10) :2540-2551

[13]

Park SH, 2015, LEUKEMIA LYMPHOMA, V25, P1

[14] PET/MR Imaging in the Detection and Characterization of Pulmonary Lesions: Technical and Diagnostic Evaluation in Comparison to PET/CT [J].

Rauscher, Isabel ;

Eiber, Matthias ;

Furst, Sebastian ;

Souvatzoglou, Michael ;

Nekolla, Stephan G. ;

Ziegler, Sibylle I. ;

Rummeny, Ernst J. ;

Schwaiger, Markus ;

Beer, Ambros J. .

JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (05) :724-729

[15] Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma [J].

Shinya, Takayoshi ;

Fujii, Soichiro ;

Asakura, Shoji ;

Taniguchi, Toshitaka ;

Yoshio, Kotaro ;

Alafate, Aierken ;

Sato, Shuhei ;

Yoshino, Tadashi ;

Kanazawa, Susumu .

ANNALS OF NUCLEAR MEDICINE, 2012, 26 (08) :616-621

[16] 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients [J].

Weiler-Sagie, Michal ;

Bushelev, Olga ;

Epelbaum, Ron ;

Dann, Eldad J. ;

Haim, Nissim ;

Avivi, Irit ;

Ben-Barak, Ayelet ;

Ben-Arie, Yehudit ;

Bar-Shalom, Rachel ;

Israel, Ora .

JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (01) :25-30

← 1 2 →